News articles about Express Scripts (NASDAQ:ESRX) have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Express Scripts earned a news impact score of 0.17 on Accern’s scale. Accern also gave media stories about the company an impact score of 47.3344369549374 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Express Scripts (ESRX) Downgraded to Hold at BidaskClub (americanbankingnews.com)
- See what the IHS Markit Score report has to say about Express Scripts Holding Co. (finance.yahoo.com)
- Express Scripts Holding Company to Cancel Investor Day Meeting (finance.yahoo.com)
- BRIEF-Express Scripts Holding Company To Cancel Investor Day Meeting (feeds.reuters.com)
- New Company Valuation, Express Scripts Reaps, Cigna Weeps … – Seeking Alpha (seekingalpha.com)
Several equities analysts have recently commented on ESRX shares. Maxim Group upped their price target on shares of Express Scripts from $78.00 to $87.00 and gave the stock a “buy” rating in a research report on Thursday, December 14th. Deutsche Bank started coverage on shares of Express Scripts in a research report on Monday, December 4th. They set a “buy” rating and a $75.00 price target for the company. Zacks Investment Research lowered shares of Express Scripts from a “buy” rating to a “hold” rating in a research report on Friday, March 2nd. SunTrust Banks set a $86.00 price target on shares of Express Scripts and gave the stock a “buy” rating in a research report on Thursday, December 21st. Finally, TheStreet upgraded shares of Express Scripts from a “c+” rating to a “b-” rating in a research report on Monday, December 4th. Three equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $81.97.
Express Scripts (NASDAQ:ESRX) last announced its earnings results on Tuesday, February 27th. The company reported $2.16 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.09 by $0.07. The firm had revenue of $25.38 billion during the quarter, compared to analyst estimates of $25.07 billion. Express Scripts had a net margin of 4.51% and a return on equity of 25.19%. Express Scripts’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.88 EPS. research analysts anticipate that Express Scripts will post 9.35 earnings per share for the current fiscal year.
Express Scripts declared that its board has authorized a stock buyback plan on Monday, December 18th that allows the company to buyback 45,000,000 shares. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.
In other news, VP Glen D. Stettin sold 3,448 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $76.00, for a total transaction of $262,048.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Glen D. Stettin sold 3,449 shares of the firm’s stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $81.00, for a total transaction of $279,369.00. Following the transaction, the vice president now owns 33,715 shares of the company’s stock, valued at approximately $2,730,915. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,896 shares of company stock valued at $1,617,903. Insiders own 0.68% of the company’s stock.
About Express Scripts
Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.